Two patients begin GLP-1 weight loss therapy on the same day. Both receive once-weekly subcutaneous semaglutide, supervised by licensed physicians, with medication delivered to their homes. One pays $1,349 per month. The other pays $149. This is not a pricing error — it is an accurate reflection of how the current market for GLP-1 medications is structured.
According to CDC NHANES data from August 2021–August 2023, 40.3% of U.S. adults meet clinical criteria for obesity (BMI ≥30).1 That is over 100 million people — and less than 3% are currently receiving pharmacotherapy. The pricing structure is the primary reason.
The four pricing tiers in 2026
- Brand-name at list price: $900–$1,349/month (Wegovy, Zepbound)
- Brand-name with insurance: $0–$200/month (with prior authorization)
- Compounded semaglutide: $149–$350/month (physician-supervised programs)
- Oral semaglutide (new 2026): $145–$299/month (FDA-approved pill)
Tier 1: Brand-Name at List Price ($900–$1,349/month)
Brand-name GLP-1 medications are priced based on pharmaceutical R&D costs (the STEP trial program for semaglutide involved tens of thousands of participants across multiple phase 3 trials), FDA approval requirements, and a pricing strategy calibrated to a market where most patients access medications through insurance with negotiated rebates. The list price primarily affects the uninsured.
Find a GLP-1 option matched to your state and budget in 60 seconds.
Get My Match →Tier 2: Brand-Name with Insurance ($0–$200/month)
Many large employer-sponsored plans and ACA marketplace plans cover Wegovy and Zepbound for patients with BMI ≥30, or ≥27 with documented comorbidities, with prior authorization. When approved, copays typically run $25–$200/month. Medicare Part D does not currently cover GLP-1s for weight management (pending legislation).
The SELECT trial — 17,604 patients, mean follow-up 39.8 months — found semaglutide 2.4 mg reduced the composite endpoint of cardiovascular death, nonfatal MI, or nonfatal stroke by 20% (HR 0.80, 95% CI 0.72–0.90, p<0.001).2 For patients with cardiovascular disease, this finding alone justifies aggressive pursuit of insurance coverage for brand-name medication.
Tier 3: Compounded Semaglutide ($149–$350/month)
The compounded semaglutide market emerged when semaglutide was on the FDA shortage list (2022–early 2025). Compounding pharmacies were legally permitted to produce copies during shortage periods under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. The active pharmaceutical ingredient is identical to Wegovy; the finished product has not undergone FDA approval as a compounded product.
Regulatory note (2026): The FDA removed semaglutide from the shortage list in February 2025. The regulatory landscape for compounded semaglutide programs continues to evolve. Ask any program about their pharmacy facility type (503A or 503B) and current FDA compliance status before enrolling.
Tier 4: Oral Semaglutide — The Emerging Middle Ground ($145–$299/month)
FDA approved an oral Wegovy formulation in December 2025. The OASIS 1 trial demonstrated oral semaglutide 50 mg produced a mean weight loss of 17.4% over 68 weeks in adults with obesity.3 Several telehealth platforms introduced oral Wegovy in early 2026 at $145–$299/month — providing an FDA-approved, needle-free option at prices approaching compounded injectables.
How to Find Your Actual Cost
Before paying out of pocket for any program, contact your insurer and ask specifically whether Wegovy (NDC: 0169-4139-15) is on formulary and what prior authorization requires. If insured and clinically eligible, you may qualify for $25–$50/month copays — dramatically lower than any cash-pay option.
If you are uninsured or coverage is unavailable, our matching tool filters programs by state and budget to show verified options at your price range.